methyl 3-hydroxy-2-iodopropanoate | 177760-41-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: methyl 3-hydroxy-2-iodopropanoate
• 英文别名: methyl 2-iodo-3-hydroxypropanoate
• CAS: 177760-41-7
• 化学式: C₄H₇IO₃
• 分子量: 230.002
• InChiKey: DJFUADYRGWVZHZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  丙烯酸甲酯（MA） 在 cerium (IV) sulfate tetrahydrate 、 水 、 碘 作用下， 以 乙腈 为溶剂， 反应 1.5h， 以49%的产率得到methyl 3-hydroxy-2-iodopropanoate
  参考文献：
  名称：

  Utsukihara, Takamitsu; Ochiai, Keiko; Koshimura, Masahiro, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2016, vol. 55B, # 12, p. 1503 - 1510

  摘要：

  DOI：

文献信息

• Aromatic amino ethers as pain relieving agents
  申请人：Zeneca Limited

  公开号：US05843942A1

  公开（公告）日：1998-12-01

  The present invention relates to compounds of formula (I), ##STR1## wherein A is an optionally substituted phenyl naphthyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidyl, thienyl, thiazolyl, oxazolyl, thiadiazolyl having at least two adjacent ring carbon atoms or a bicyclic ring system, provided that the --CH(R.sup.3)N(R.sup.2)B--R.sup.1 and --OCH(R.sup.4 --)--D linking groups arm positioned in a 1,2 relationship to one another on ring carbon atoms and the ring atom positioned ortho to the --OCHR.sup.4 -- linking group (and therefore in the 3-position relative to the --CHR.sup.3 NR.sup.2 -- linking group) is not substituted; B is an optionally substituted ring system; D is an optionally substituted ring system; R.sup.1 is a variety of group as defined in the description; R.sup.2 is hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, phenylC.sub.1-3 alkyl or 5- or 6-membered heteroarylC.sub.1-3 alkyl; R.sup.3 is hydrogen or C.sub.1-4 alkyl; R.sup.4 is hydrogen or C.sub.1-4 alkyl; and N-oxides of NR.sup.2 where chemically possible; and S-oxides of sulphur containing rings were chemically possible; and pharmaceutically acceptable salts and in vivo hydrolysable esters and amides thereof. Process for their preparation, intermediates in theirpreparation, their use as therapeutic agents and pharmaceutical compositions containing them.

  本发明涉及如下式(I)的化合物，其中A是一个可选择取代的苯基萘基、吡啶基、吡嗪基、吡啶啉基、嘧啶基、噻吩基、噻唑基、噁唑基、噻二唑基，具有至少两个相邻环碳原子或双环环系统的环，前提是--CH(R^3)N(R^2)B--R^1和--OCH(R^4)--D连接基位于环碳原子上呈1,2关系，并且位于与--OCHR^4--连接基相邻的环原子（因此相对于--CHR^3 NR^2--连接基位于3位置）未被取代；B是一个可选择取代的环系统；D是一个可选择取代的环系统；R^1是描述中定义的各种基团；R^2是氢、C_1-6烷基、C_2-6烯基、C_2-6炔基、苯基C_1-3烷基或5-或6-成员的杂环基C_1-3烷基；R^3是氢或C_1-4烷基；R^4是氢或C_1-4烷基；NR^2的N-氧化物在化学上可能；含硫环的S-氧化物在化学上可能；以及其药学上可接受的盐和体内可水解的酯和酰胺。其制备方法，制备中间体，用作治疗剂的用途以及含有它们的药物组合物。
• IBX−I₂Redox Couple for Facile Generation of IOH and I⁺: Expedient Protocol for Iodohydroxylation of Olefins and Iodination of Aromatics
  作者：Jarugu Narasimha Moorthy、Kalyan Senapati、Sarvesh Kumar

  DOI：10.1021/jo9007892

  日期：2009.8.21

  IBX is readily reduced to IBA in the presence of molecular iodine in DMSO to generate hypoiodous acid (IOH). which reacts with a variety of olefins as well as alpha, beta-unsaturated ketones leading to their respective iodohydrins with anti stereochemistry. The same redox chemistry in acetonitrile containing TFA produces iodonium lolls for facile Iodination of a variety of aromatic compounds in respectable isolated yields.